NSI-189 is a benzylphiperizine-aminiopyridine, nootropic and neurogenic
research chemical created by Neuralstem, Inc. that was derived from
pyrazine and nicotinamide. Studies have shown that it stimulates
neurogenesis of human hippocampus-derived neural stem cells in vivo and
vitro. In healthy adult mice, NSI-189 has been shown to increase the
hippocampal volume by 20% and reverse behavioral symptoms in mouse
depression models, meaning at the source it could address depression.
The hippocampus is responsible for spatial navigation, along with the
consolidation of information from short-term memory to long-term memory.
NSI 189 phosphate powder
The chemical entity stimulates new neuron growth in the hippocampus,
which is an area of the brain that is believed to be contributory in
conditions such as post-traumatic stress disorder (PTSD), Alzheimer's
disease, and major depressive disorder (MDD).
Tests have shown that NSI-189 significantly improved behavioral
responses that are associated with depression . In humans it may counter
hippocampal atrophy which is seen in disorders such as MDD, reversing
their symptoms. A phase 1B randomized, double-blind, placebo-controlled,
multiple-dose escalation study conducted over a 28 day period showed
behavioral efficacy in 24 patients who were orally administered NSI-189 .
The efficacy measurements showed a clinically meaningful reduction in
cognitive and depressive symptoms across all measures, and appeared to
persist over time during follow up for the efficacy assessments which
included the Clinical Global Impression - Improvement (CGI-I),
Montgomery-Aserb Depression Rating Scale (MADRS), Cognitive and Physical
Functioning Questionnaire (CPFQ, and the Symptoms of Depression
Questionnaire (SDQ).
The Wall